

Human / Cynomolgus VEGF / VEGFA / VEGF165 Protein

Catalog Number: 11066-HNAB



Sino Biological Inc.

Biological Solution Specialist

General Information

Gene Name Synonym:

RP1-261G23.1, MGC70609, MVCD1, VEGF, VEGF-A, VPF

Protein Construction:

A DNA sequence encoding the human VEGF 165 isoform (P15692-4) (Met1-Arg191) was expressed. Human and Cynomolgus VEGF165 sequences are identical.

Source: Human

Expression Host: Baculovirus-Insect Cells

QC Testing

Purity: > 98 % as determined by SDS-PAGE

Bio-Activity

Measured in a cell proliferation assay using human umbilical vein endothelial cells (HUVEC). The ED50 for this effect is typically 3-5 ng/ml.

Endotoxin:

< 1.0 EU per µg of the protein as determined by the LAL method

Stability:

Samples are stable for up to twelve months from date of receipt at -70 °C

Predicted N terminal: Ala 27

Molecular Mass:

The recombinant human VEGF consists of 165 amino acids after removal of the signal peptide and predicts a molecular mass of 19.2 kDa. Due to different glycosylation, the apparent molecular mass of rhVEGF165 is approximately 20 and 22 kDa in SDS-PAGE under reducing conditions, corresponding to the monomer.

Formulation:

Lyophilized from sterile PBS, pH 7.4

Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. Please contact us for any concerns or special requirements.


Usage Guide

Storage:

Store it under sterile conditions at -20°C to -80°C upon receiving. Recommend to aliquot the protein into smaller quantities for optimal storage.

Avoid repeated freeze-thaw cycles.

SDS-PAGE:



Reconstitution:

Detailed reconstitution

re products.

Protein Description

Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF) and VEGF-A, is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. It is a member of the platelet-derived growth factor (PDGF)/vascular endothelial growth factor (VEGF) family and often exists as a disulfide-linked homodimer. VEGF-A is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. As its name implies, VEGF-A activity has been mostly studied on cells of the vascular endothelium, although it does have effects on a number of other cell types (stimulation monocyte/macrophage, neurons, cancer cells, kidney epithelial cells). VEGF-A is also a vasodilator and increases microvascular permeability and was originally referred to as vascular permeability factor. Alternatively spliced transcript variants of VEGF-A, encoding either secreted or cell-associated isoforms, have been identified. Alternatively spliced isoforms of 121,145,165,183,189 and 206 amino acids in length are expressed in humans. VEGF165 appears to be the most abundant and potent isoform and is a heparin-binding growth factor with mitogenic activity for vascular endothelial cells. Human VEGF165 shares 88%, 96%, 95% and 93% aa sequence identity with mouse, porcine, canine and feline VEGF165, respectively.

References

1. Mattei, M.G. et al., 1996, Genomics. 32 (1):168-169.
2. Borgatti, P. et al., 1998, Eur. J. Immunol. 27 (11): 2805-2811.
3. Gengrinovitch, S. et al., 1999, J Biol Chem. 274 (16):10816-10822.
4. Zachary, I. et al., 2001, Cardiovasc. Res. 49: 568-581.
5. Robinson, C.J. et al., 2001, J. Cell. Sci. 114: 853-865.
6. Lee, P. et al., 2002, Proc. Natl. Acad. Sci. USA. 99: 10470-10475.
7. Lee, G.Y. et al., 2006, Protein expressed and Purification. 46: 503-509.

Manufactured By Sino Biological Inc., FOR RESEARCH USE ONLY. NOT FOR USE IN HUMANS.

Fax :+86-10-51029969 • Tel:+86-400-890-9989 • <http://www.sinobiological.com>